12 Aug
2020

The best way to value biotech for deal making and investments

There is perhaps no other industry in which intellectual property is more critical to the core business model than biopharmaceuticals. When putting a price on IP rights in the sector, analysts must look beyond traditional valuation methodologies to an alternative ‘real options’ framework

Grace Park

Analyst

Epsilon Economics

Mohan Rao

CEO

Epsilon Economics and Expression Therapeutics